Xarelto was approved by the U.S. Food and Drug Administration (FDA) in October 2011 [1]. It received approval for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
When does Xarelto's patent expire?
Information regarding Xarelto's patent expiry can be found on DrugPatentWatch.com [2]. Patent expirations are crucial as they can pave the way for generic competition.
What other conditions is Xarelto approved for?
Following its initial approval, Xarelto has received additional indications. It was approved for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone hip or knee replacement surgery [1]. Further approvals included the treatment of DVT and PE, and the reduction of the risk of recurrent DVT and PE [1]. Xarelto is also approved for reducing the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease [1].
How does Xarelto work?
Xarelto, with the active ingredient rivaroxaban, is a direct factor Xa inhibitor [3]. By inhibiting factor Xa, it interferes with the coagulation cascade, thereby reducing thrombin generation and preventing the formation of blood clots [3].
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, as with other anticoagulants, is an increased risk of bleeding [1]. This bleeding can be serious and, in some cases, life-threatening [1]. Patients and healthcare providers must carefully weigh the benefits of preventing clots against the risk of bleeding when considering Xarelto [1].
Who makes Xarelto?
Xarelto is a medication developed by Bayer and is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [4].
Can generic versions of Xarelto be made?
The development of generic versions of Xarelto is contingent upon patent expiry and regulatory approval. Once patents expire, companies can apply to the FDA for approval to market generic versions, which would then be available for prescription [2].
What alternatives exist for Xarelto?
Several other anticoagulant medications are available, including warfarin, apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa) [5]. These alternatives also work to prevent blood clots but may have different mechanisms of action, dosing regimens, and risk profiles [5]. The choice of anticoagulant depends on individual patient factors, medical history, and physician recommendations [5].
What is the difference between Xarelto and warfarin?
Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC), while warfarin is a vitamin K antagonist [3]. DOACs generally offer more predictable pharmacokinetics and pharmacodynamics, often eliminating the need for routine monitoring of blood clotting parameters, which is typically required with warfarin [3]. However, warfarin has a longer history of use and an established antidote, whereas reversal agents for DOACs are more recent [3].
---
Sources:
[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-database/drug-approval-packages
[2] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[3] Xarelto (rivaroxaban) Prescribing Information. (n.d.). Retrieved from https://www.janssen.com/xarelto/hcp/prescribing-information
[4] Bayer AG. (n.d.). Our Products. Retrieved from https://www.bayer.com/en/products
[5] U.S. National Library of Medicine. (n.d.). Anticoagulants (Blood Thinners). Retrieved from https://medlineplus.gov/anticoagulantsbloodthinners.html